Kyverna to partner with ElevateBio for commercial manufacturing of miv-cel
Kyverna Therapeutics announced a manufacturing agreement with ElevateBio to secure supply for its CAR-T therapy, miv-cel, supporting Q4 BLA submissions. This agreement strengthens commercial readiness for autoimmune indications like SPS and gMG.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day